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Abstract
The Immunodeficiency, Centromeric region instability, Facial anomalies syndrome (ICF) is a rare
autosomal recessive disease described in about 50 patients worldwide and characterized by
immunodeficiency, although B cells are present, and by characteristic rearrangements in the vicinity
of the centromeres (the juxtacentromeric heterochromatin) of chromosomes 1 and 16 and
sometimes 9. Other variable symptoms of this probably under-diagnosed syndrome include mild
facial dysmorphism, growth retardation, failure to thrive, and psychomotor retardation. Serum
levels of IgG, IgM, IgE, and/or IgA are low, although the type of immunoglobulin deficiency is
variable. Recurrent infections are the presenting symptom, usually in early childhood. ICF always
involves limited hypomethylation of DNA and often arises from mutations in one of the DNA
methyltransferase genes (DNMT3B). Much of this DNA hypomethylation is in 1qh, 9qh, and 16qh,
regions that are the site of whole-arm deletions, chromatid and chromosome breaks, stretching
(decondensation), and multiradial chromosome junctions in mitogen-stimulated lymphocytes. By an
unknown mechanism, the DNMT3B deficiency that causes ICF interferes with lymphogenesis (at a
step after class switching) or lymphocyte activation. With the identification of DNMT3B as the
affected gene in a majority of ICF patients, prenatal diagnosis of ICF is possible. However, given the
variety of DNMT3B mutations, a first-degree affected relative should first have both alleles of this
gene sequenced. Treatment almost always includes regular infusions of immunoglobulins, mostly
intravenously. Recently, bone marrow transplantation has been tried.
Disease name and synonyms
Immunodeficiency, Centromeric instability, and Facial
anomalies syndrome was given the acronym ICF in 1988
[1]. ICF is an autosomal recessive disease. Note that the
instability is not in the centromere itself, but rather in the
region adjacent to the centromere (qh), predominantly in
chromosomes 1 and 16.
Definition/diagnostic criteria
ICF (OMIM #24242860) is a rare autosomal recessive dis-
ease that involves agammaglobulinemia or hypoglob-
ulinemia with B cells as well as DNA rearrangements
targeted to the centromere-adjacent heterochromatic
region (qh) of chromosomes 1 and/or 16 (and sometimes
9) in mitogen-stimulated lymphocytes. The frequency of
these rearrangements is high enough to be detected upon
routine cytogenetic examination of metaphase chromo-
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somes. These rearrangement-prone heterochromatic
regions exhibit DNA hypomethylation in all examined
ICF cell populations. The three invariant features of ICF
are the immunodeficiency despite the presence of B cells;
characteristic rearrangements of chromosome 1 and/or 16
with breakpoints at 1qh and 16qh in mitogen-stimulated
lymphocytes; and hypomethylation of classical satellite 2
and 3 DNA, the main DNA components of 1qh, 16qh,
and 9qh [2], in leukocytes, other tissues, and cell cultures
from ICF patients.
Epidemiology
ICF is an autosomal recessive disease, with approximately
50 patients reported worldwide since it was first described
in the late 1970's [3,4]. The patients come mostly from
Europe. However, ICF patients are of diverse ethnicity,
including European, Turkish, Japanese, and African Amer-
ican. Some excess of consanguinity has been noted [5-7],
although most cases are not familial. Recently, there has
been a sharp increase in the number of diagnosed, non-
familial cases in Europe and Japan, which suggests that
this disease is underdiagnosed, especially in the United
States, where only a few cases have been reported [8,9].
Etiology
Mutations in DNMT3B coding sequences
The locus for ICF was localized to 20q11-q13 by homozy-
gosity mapping [10]. This led to the discovery that the
DNMT3B gene is often the site of ICF mutations [11-13].
In the 35 ICF patients analyzed to date for DNMT3B
mutations, 57% had mutations in both DNMT3B alleles
(OMIM #602900) within the coding portion [5,14-16].
These mutations are frequently found in the C-terminal
portion of the protein that contains the catalytic domain
[17] and are often missense mutations [11,13,14,18,19].
Although DNMT3B has repressor activity that is inde-
pendent of its DNA methyltransferase activity, repression
involves the central portion of the protein, which does not
overlap with the methyltransferase domain [20].
DNMT3B also forms a complex with DNMT1 and with
small ubiquitin-like modifier 1, but these interactions
involve the N-terminus of DNMT3B [21,22]. In contrast,
many ICF patients have a missense mutation in one or
both of their mutant alleles to give an amino acid substi-
tution in one of ten motifs conserved among all cytosine-
C5 methyltransferases [17]. These findings suggest that it
is the loss of DNA methyltransferase activity, and not
some other function of the protein, that is responsible for
the syndrome. The involvement of DNA hypomethylation
in the phenotype of ICF is supported at the cytogenetic
level because the ICF-specific rearrangements in mitogen-
treated lymphocytes are the same in frequency, spectrum,
and chromosomal specificity as those found in a normal
pro-B lymphoblastoid cell line treated with the DNA
methylation inhibitors 5-azacytidine or 5-azadeoxycyti-
dine [23,24]. Also, biochemical analyses of recombinant
proteins with known ICF mutations [17] and the invariant
hypomethylation of certain portions of the genome from
ICF patients [25,26] are consistent with ICF being due to
a deficiency in DNA methylation.
Mutations outside DNMT3B coding sequences
For the ~40% of ICF patients with no mutations discov-
ered in exonic DNA from DNMT3B, there might be muta-
tions in the promoter or other transcription control
elements or mutations affecting splicing or polyadenyla-
tion. However, for several of these ICF patients without
detected DNMT3B mutations, the most common isoform
of DNMT3B RNA was still observed [15], and for the one
patient examined in two putative promoter regions of
DNMT3B, no mutations were found [16]. The patients
without DNMT3B coding region mutations seem to be
derived from a different subtype of ICF. Lymphocytes or
fibroblasts from 9 out of 9 patients in this category dis-
played hypomethylation in satellite α (centromeric) DNA
while 5 out of 5 patients who had mutations in DNMT3B
did not [15]. ICF patients, including those without dem-
onstrated mutations in DNMT3B, invariantly exhibit
hypomethylation in the major DNA component of 1qh
and 16qh (classical satellite 2 DNA) and of 9qh (classical
satellite 3 DNA) in all examined tissues and in B-cell lines.
In addition, they display chromosomal anomalies at 1qh
and 16qh in mitogen-stimulated cells [16,25,27,28]. As
described below, it is unclear how the limited amount of
DNA demethylation associated with ICF (a 7% decrease
in the genomic 5-methylcytosine level in ICF tissue com-
pared to that in normal tissue [28]) may cause the immu-
nodeficiency and other variable symptoms associated
with the disease.
One other genetic disease, the X-linked α-thalassemia/
mental retardation syndrome (ATR-X linked syndrome),
is associated with an apparently Mendelian inheritance of
DNA methylation abnormalities in a small part of the
genome [29,30]. This syndrome is accompanied by either
decreases (satellite 1 in Yqh but not in satellites 2 or 3) or
increases (ribosomal RNA genes) in DNA methylation,
apparently as a result of mutations in a putative ATP-
dependent DNA helicase. ICF is the only human genetic
disease currently known to involve mutations in a DNA
methyltransferase gene. In mice, insertional inactivation
of Dnmt3b or of the other two main DNA methyltrans-
ferase genes, Dnmt1 and Dnmt3a, results in prenatal death
or (for Dnmt3a) death several weeks after birth [18]. It is
likely that ICF-causing mutations in DNMT3B leave resid-
ual activity, otherwise embryonic lethality would proba-
bly result. This is consistent with analyses of the
biochemical effects of ICF-associated mutations on
DNMT3B activity in vitro [17]. Therefore, homozygousOrphanet Journal of Rare Diseases 2006, 1:2 http://www.OJRD.com/content/1/1/2
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null DNMT3B (or DNMT1 or DNMT3A) mutations might
make a small contribution to spontaneous abortions.
Clinical description
Immunodeficiency
The immunodeficiency, despite the presence of B cells
almost always [31], results in severe recurrent infections,
often seen in early childhood and usually as the present-
ing finding [32,33]. A review of the literature shows that
almost all ICF patients have severe respiratory infections
and more than half have recurrent gastrointestinal infec-
tions. Pericarditis, ear infections, septicemia, and oral
Candida infections have also been observed [19,34,35].
The immunodeficiency in ICF patients ranges from agam-
maglobulinemia to a mild reduction in immune response
[36]. Most patients have a poor immune response with
low amounts or undetectable levels of IgA, IgG and/or
IgM [14], but the exact nature of the immunodeficiency is
variable. For example, in some patients only certain sub-
classes of IgG display deficiencies [14,37], while in others,
there are very low levels of IgG, IgA, and IgM or just of two
of these three classes of immunoglobulins [26]. Low lev-
els of T-cells are present in about half of the patients and
levels of B cells are also sometimes low, although in some
patients only one or the other type of lymphocyte shows
reduced levels [34,35,38].
Facial anomalies
The dysmorphic facial features are variable [31,34] and
usually mild; moreover, several patients did not display
them (unpub. data). The typical facial features are a broad
flat nasal bridge, hypertelorism (very widely spaced eyes),
and epicanthic folds. Less frequent, but still often associ-
ated with the syndrome, are micrognathia (small jaw),
low-set ears, and macroglossia (protrusion or enlarge-
ment of the tongue) [1,5,19,34,39,40].
Psychomotor delay
Mental retardation and neurologic defects have been seen
in about one-third and one-fifth of the patients, respec-
tively [31,34,37], and include slow cognitive and motor
development and psychomotor impairment (ataxic gait
and muscle hypotonia) [3,8,31,41]. In one case, delayed
psychomotor development changed into age-appropriate
development at 36 months [35].
Other abnormalities
Other congenital abnormalities in ICF are highly variable.
Intrauterine growth retardation has been observed in ICF
patients [34,39,40]. Several patients have been described
with protruding abdomens [34,40] and thin arms and legs
[34]. At least two patients have been found to have bipar-
tite nipples [37]. Skin pigment changes have been seen in
some patients, with café au lait spots or irregularly out-
lined mildly hyperpigmented spots reported [3,6,37].
Scleral telangiectasias were found in at least one patient
[37].
Diagnostic methods
Peripheral blood karyotype
Chromosomal anomalies
ICF is diagnosed by standard metaphase chromosome
analysis of peripheral blood from paediatric patients
(often babies or toddlers) displaying otherwise unex-
plained recurrent infections, which are usually severe pul-
monary or gastrointestinal infections, despite the
presence of B cells. Metaphases from phytohemaggluti-
nin-stimulated blood cultures exhibit the following
anomalies: whole-arm deletions and pericentromeric
breaks of chromosomes 1 and 16 and sometimes 9; multi-
branched chromosomes containing three or more arms of
chromosomes 1 and 16 joined in the vicinity of the cen-
tromere (mostly at the 1qh or 16qh region); and occa-
sional isochromosomes and translocations with breaks in
the vicinity of the centromere [3,8,28,34]. In addition,
prominent stretching (decondensation) in the 1qh and
16qh region is seen in chromosomes 1 and 16. Stimula-
tion of ICF blood cultures with pokeweed mitogen pro-
duces similar anomalies. In most, but not all patients,
chromosome 1 is affected more frequently than chromo-
some 16.
Although many patients have low in vitro stimulation
indices for either phytohemagglutinin or pokeweed
mitogen, this is not an invariant finding and sufficient
metaphases accumulate for cytogenetic analysis. Standard
metaphase analysis after incubation of blood with
mitogen for 72 or 92 hours allows the development of
maximal frequencies of the ICF-associated chromosomal
rearrangements [3,40,42].
Number of metaphases needed to be analysed
Examination of 20 G-banded metaphases is generally ade-
quate to reveal the characteristic cytogenetic anomalies of
ICF because the frequency of chromosomal anomalies at
1qh and or 16qh is so high in mitogen-stimulated T cells
from ICF patients, especially at 48-92 hours after stimula-
tion (compared to examining metaphases 24 hours after
stimulation; reviewed in [26]). However, given the cen-
trality of cytogenetics in the diagnosis of ICF, it would be
preferable to examine 50 metaphases to increase the
chance of seeing the ICF-specific multiradial chromo-
somes with arms from chromosomes 1 and/or 16 joined
in the pericentromeric region.
Sometimes there are rearrangements at 9qh [1,3,7,31,43],
but even when they are present, chromosome 1 or 16 rear-
rangements predominate. The 9qh DNA consists largely
of classical satellite 3 DNA. Satellite 3 DNA is also
hypomethylated in ICF patients [44]. There have been rareOrphanet Journal of Rare Diseases 2006, 1:2 http://www.OJRD.com/content/1/1/2
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findings of rearrangements at chromosomes 10 and 2
[40,42], both of which have short heterochromatic juxta-
centromeric regions rich in classical satellite 2 [2]. There is
no increase in sister chromatid exchange in ICF samples.
Several ICF patients had aberrations in skin fibroblasts as
well as in mitogen-stimulated lymphocytes [43], and one
had the characteristic ICF-type chromosome rearrange-
ments in bone marrow [8]. However, because bone mar-
row cells and skin fibroblast cultures from many of the
analyzed patients show little or no recombination at 1qh,
16qh, and 9qh [3,4,6,8,34,43], these cell types should not
be used for diagnosis. Parental chromosomes are gener-
ally normal, just as heterozygous parents show no pheno-
type.
Differential diagnosis
Like Bloom syndrome (BS), ataxia-telangiectasia (AT),
and Nijmegen breakage syndrome (NBS), ICF is usually
diagnosed in children and involves spontaneous chromo-
some instability and immunodeficiency [26,37,45-49].
Growth retardation, psychomotor disturbances, or mental
retardation is seen in some ICF patients as well as in BS
and NBS patients. The ICF-specific cytogenetic abnormal-
ities, which are observed in mitogen-stimulated lym-
phocytes, consist predominantly of whole-arm deletions
or breaks, multiradial (multibranched) chromosomes,
and decondensation (stretching) involving heterochro-
matin in the vicinity of the centromeres of chromosomes
1 and 16 [26,34,43]. These chromosomal anomalies are
distinct from those of other syndromes, e.g., abnormally
high levels of rearrangements at the immunoglobulin
superfamily loci of chromosomes 7 and 14, which are
found in T cells from AT and NBS patients [45-47]. Sister
chromatid exchange rates are normal in ICF patients [43],
distinguishing ICF from BS, in which elevated rates of sis-
ter chromatid exchange are a cytological hallmark of the
disease [49,50]. The multiradial chromosomes in stimu-
lated lymphocytes from ICF patients have 3 to 10 arms of
chromosomes 1 and/or 16, sometimes in combination
with chromosome 9; the region of chromosome fusion is
always in the vicinity of the centromere (usually the qh
region) and predominantly in chromosomes 1 and 16
[26,34]. Although stimulated lymphocytes from BS
patients may display multiradial chromosomes, these
chromosomal abnormalities are mostly quadriradials
without the strong regional and chromosomal specificity
seen in mitogen-stimulated ICF lymphocytes [49,51].
Facial anomalies in BS (small narrow face with a dwarfed
body) and NBS (bird-like face) and frequent characteristic
dermatological abnormalities in AT, NBS, and BS
[46,52,53] also distinguish these syndromes from ICF.
AT, NBS and BS are each associated with greatly increased
frequencies of cancer, and an unusually high frequency is
observed in children with NBS [45,50,54]. No cancers
have been reported in ICF patients, who often die during
childhood, like NBS patients. However, there was one
recent report of a benign tumor in a 3-year-old ICF patient
[16]. ICF, like AT, BS and NBS, makes cells hypersensitive
to certain chemical or physical DNA-damaging agents,
although unlike AT and NBS, cell cycle checkpoints in ICF
appear to be normal [46,50,55]. Also, ICF T-cells in phy-
tohemagglutinin-stimulated peripheral blood samples are
more prone to spontaneous apoptosis than are analogous
control cultures [38], which may help prevent tumors
forming from cytogenetically abnormal ICF cells.
Antenatal diagnosis
Karyotype
Mitogen-stimulated blood samples from unaffected indi-
viduals rarely display abnormalities in the vicinity of the
centromeres of chromosomes 1, 16, and 9, in contrast to
analogous cultures from ICF patients. However, 2% of
metaphases from random chorionic villus (CV) cultures at
day 8 displayed 1qh or 16qh decondensation and, less fre-
quently, pericentromeric breaks, whole-arm deletions,
quadriradials, or triradials [56]. Furthermore, yet higher
frequencies of these types of chromosomal aberrations
have been reported by others in CV cultures [57]. One
exceptional CV sample taken during routine screening
exhibited four cells with pericentromeric breaks in chro-
mosome 1 and seven cells with decondensation of 1qh
out of a total of 20 examined metaphases, even though
the amniotic fluid-derived culture was normal and the
patient, at almost 2 years of age, appeared normal [56].
Furthermore, high-passage cells in CV or amniotic fluid-
derived (AF) cultures from normal individuals routinely
display high frequencies of ICF-like karyotypic abnormal-
ities, although AF cultures require more passages to dis-
play these anomalies [58]. The chromosomal metaphase
anomalies in late-passage AF cultures are largely restricted
to 1qh and 16qh decondensation, while those from mid-
or late-passage CV cultures exhibit 1qh and 16qh
decondensation and, in addition, whole-arm deletions,
chromosome breaks, and multiradials involving the 1qh
or 16qh region. Also, some control B-cell lines after long-
term passage develop ICF-like chromosomal abnormali-
ties, which appear to increase in frequency if satellite 2
becomes spontaneously demethylated upon prolonged
cell culture [59,60], but 1qh decondensation has been
observed even in a control cell line that did not exhibit
ICF-like hypomethylation of satellite 2 (M. Ehrlich, L. Qi,
R. Nishiyama, and C. Tuck-Muller, unpub. data).
Fasth et al. [6] reported on AF cells taken at the time of a
cesarean section of a 34-week sibling of an ICF patient.
Five out of 15 metaphases in the AF culture showed
decondensation (despiralization) of the heterochromatic
region of chromosome 1. This was also reported in theOrphanet Journal of Rare Diseases 2006, 1:2 http://www.OJRD.com/content/1/1/2
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bone marrow cells from the affected sibling. At birth, the
younger sibling had 90% of lymphocytes showing despi-
ralization or a break in the juxtacentromeric heterochro-
matin of chromosome 1. From the above-mentioned
studies, short-term AF cultures are less likely to have cul-
ture-associated chromosomal artifacts than analogous CV
cultures. Fetal blood sampling (cordocentesis) has been
successful in at least one family [61].
Linkage analysis
Linkage analysis via CV sampling  at 12 weeks of gestation
was reported  [62]. Linkage markers from a 9-cM region of
chromosome 20, at which the ICF locus had been mapped
at that time, were used. A marker, D20S850, was inform-
ative, indicating that the fetus was heterozygous for the
gene. The couple was given a greater than 90% probability
that the fetus was not affected with ICF. Cordocentesis
was declined, and postnatal blood chromosome analysis
revealed a normal male karyotype, without juxtacentro-
meric heterochromatin instability.
DNA sequence analysis
DNA analysis of the DNMT3B gene is also being done on
a research basis in some laboratories, and could be used
for diagnosis. However, because of the variety of muta-
tions in DNMT3B that cause this syndrome [5,15], it is
feasible only for analyzing close relatives in ICF families
with known DNMT3B mutations. Therefore, this prenatal
diagnosis requires a first-degree affected relative who had
sequenced mutations in both alleles.
Management including treatment
Intravenous infusion of gammaglobulin has been success-
ful in some ICF patients [35]. In the Netherlands, nearly
all ICF patients receive regular infusions of immunoglob-
ulins, mostly intravenously (IVIG), and the treatment goal
is to reach a serum IgG level of 5 g/l in the child (C.M.R.
Weemaes, unpub. data). Treatment with IVIG reduces the
severity and frequency of infections in most patients. Ear-
lier treatment with IVIG, as can be done if ICF is diag-
nosed shortly after birth (such as in the case of younger
siblings of known affected patients) can help prevent the
gastrointestinal symptoms in some patients. However,
most patients suffer from some T-cell defect as well.
Patients can develop opportunistic infections such as
Pneumocystis carinii (PCP), Cytomegalovirus, and Candida,
even if they have normal levels of T-cell subpopulations.
Prophylactic use of trimethoprim-sulfamethoxazole to
prevent PCP seems to be indicated in some patients.
Improved anti-microbial therapy for ICF is leading to
more ICF patients reaching adulthood than previously
recorded. This may result in other manifestations of
immunodeficiency, such as progressive multifocal leu-
koencephalopathy, which was recently described in a 40-
year-old ICF patient as a result of infections with James-
town Canyon virus (JCV) [63].
Prognosis
Prognosis varies depending on several factors [43]. Com-
mon causes of death are from opportunistic infections or
pulmonary infections. The prognosis is poor in children
with gastrointestinal problems that lead to intractable
diarrhea and failure to thrive. In the absence of combined-
type immunodeficiency, the clinical course is often more
favorable. Successful bone marrow transplantation has
been performed in two ICF children recently (Weemaes,
unpub. data).
Discussion and unresolved questions
1. How do mutations in DNMT3B and the resulting 
deficiency in DNA methyltransferase activity cause ICF?
It is not clear how DNA hypomethylation in ICF patients
may result in the immunodeficiency. However, it seems
likely, as described under "Etiology," that it is the DNA
methylation deficiency, and not some other aspect of
impaired DNMT3B activity, that is responsible for the dis-
ease. Hypomethylation in some region(s) of the genome
probably changes transcription of one or more genes that
are primary targets for the deficiency in DNMT3B activity.
The immunodeficiency in ICF is manifested as low serum
immunoglobulin levels, although there can be normal B-
and T-cell numbers in peripheral blood. The latter finding
indicates that the early stages of lymphocyte differentia-
tion are not abnormal. High percentages of cells in ICF B-
cell lines that have membrane-bound IgM and/or IgD
have been observed even in patients with extremely low
levels of IgM. Therefore, class switching was normal for
the precursors of these cells, but there seems to be a defect
in lymphocyte maturation or activation [14]. In a compar-
ison of ICF lymphoblastoid cell lines (B-cell lines with
known DNMT3B mutations) and analogous control cell
lines by a microarray expression analysis, only a small
number of genes, including IgG- and IgA-encoding
sequences, were found to have ICF-specific differences in
RNA levels [14]. A larger microarray expression analysis,
which was followed by quantitative real-time reverse tran-
scription-polymerase chain reaction (RT-PCR) for selected
genes, gave similar findings (M. Ehrlich, C. Sanchez, C.
Shao, R. Kuick, S. Hanash, unpub. data). In the first study,
no ICF-specific differences in promoter methylation were
seen, even for genes with elevated RNA levels in ICF cell
lines [14] and similar methylation analyses are underway
for selected genes from the second study. A number of
reports of promoter-region hypomethylation in ICF cells,
including in the inactive X chromosome, have revealed
inconsistent hypomethylation at given gene regions
among different patients [32,36,64,65]. This finding
matches results from a genome-wide search for consist-Orphanet Journal of Rare Diseases 2006, 1:2 http://www.OJRD.com/content/1/1/2
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ently hypomethylated DNA sequences in ICF vs. control
B-cells lines by 2-dimensional gel electrophoresis of DNA
digested with two restriction endonucleases, one of which
was CpG methylation-sensitive [66]. Only repeated DNA
sequences (a subtelomeric repeat and a repeat from the
acrocentric chromosomes) were identified as hypometh-
ylated specifically in all the ICF samples by this analysis.
It has been hypothesized that in ICF lymphoid cells,
hypomethylation of regions of the genome that are nor-
mally constitutively heterochromatic (e.g., 1qh and 16qh)
could affect regulation of expression of genes elsewhere in
the genome by altering the postulated normal sequestra-
tion of DNA sequence-specific proteins at this heterochro-
matin [14,26]. There are precedents for such binding of
transcription factors to centromeric heterochromatin
[67,68]. The hypothesis that constitutive heterochromatin
itself can act in trans to modulate gene expression remains
to be tested for ICF cells. Alternatively, there may be only
a small number of currently unidentified gene regions
with consistent hypomethylation specific to ICF lym-
phoid cells that are responsible for ICF-type immune dys-
function.
2. Which genes are indirectly affected so as to directly 
cause the immunodeficiency?
As explained above, the effect of the ICF DNMT3B muta-
tions on immune functions is likely to be the result of
DNA hypomethylation, probably through one or more
genes that initiate the abnormalities in late maturation
and activation of lymphoid cells. The above-mentioned
microarray expression analyses [[14], M. Ehrlich, C.
Sanchez, C. Shao, R. Kuick, and S. Hanash, unpub. data]
indicate that there are a small number of candidate genes
for ICF-specific alterations in gene expression that might
determine the phenotype. These include genes that are
involved in cell signaling, transcription control, or chro-
matin remodeling. It was suggested that altered RNA lev-
els in ICF B-cells compared to control cells might simply
be a reflection of an abnormally prevalent immature state
of these cells in vivo [26,69]. However, the genes that dis-
played ICF-specific differences in RNA levels, other than
the immunoglobulin sequences, were not those predicted
to be differentially expressed just because the ICF B-cell
lines may have been derived from less mature cells than is
normally the case. More research is needed to test which
of these microarray candidates might be the proximal
gene(s) involved in the lymphogenesis dysregulation in
ICF patients as a result of DNMT3B mutations.
3. What is the relationship between DNMT3B mutations 
and the chromosome instability of ICF?
No obvious candidate genes for the ICF chromosome
instability have been found from the above-mentioned
microarray studies on ICF B-cell lines that exhibit high fre-
quencies of 1qh or 16qh anomalies vs. control cell lines.
It is possible that the hypomethylation of the satellite
DNA in these regions in certain types of cells is responsi-
ble by itself for these chromosomal aberrations. However,
most early-passage cultures from normal chorionic villi
do not display appreciable numbers of abnormalities in
these regions, despite the hypomethylation of 1qh and
16qh DNA in these cells due to the cell's extraembryonic
mesodermal origin [56,58]. Therefore, there must be a
cell-type specificity to this chromosome instability, which
is in accord with the lower frequency of chromosomal
abnormalities in bone marrow cells and fibroblasts from
ICF patients than that found in stimulated lymphocytes
[26]. Moreover, the 1qh satellite DNA hypomethylation is
not required for decondensation in these regions because
normal amniotic fluid-derived cultures at late passage
(essentially only embryonic fibroblasts) show high fre-
quencies of 1qh decondensation despite a very high level
of satellite DNA methylation at 1qh [58]. It is likely that
there is a DNA methylation-independent pathway (prob-
ably involving epigenetic chromatin changes) and a DNA
methylation-stimulated pathway for decondensation and
rearrangements targeted to the 1qh and 16qh regions.
These mechanisms need to be elucidated. Further studies
are also necessary to elucidate why there is a much lower
frequency of these abnormalities in the 9qh region,
despite the 9qh region usually being almost as long as the
1qh region and much longer than the 16qh region. More-
over, 9qh is predominantly composed of a similar DNA
sequence (classical satellite 3; [2]) to that of classical sat-
ellite 2 in 1qh and 16qh and, like 1qh, displays ICF-spe-
cific DNA hypomethylation of its satellite DNA.
As to the relationship in metaphase between 1qh and
16qh decondensation and 1qh and 16qh rearrangements,
there is evidence that ICF B-cell lines compared to con-
trols show decondensation in these juxtacentromeric het-
erochromatin regions even in interphase and that 1qh and
16qh exhibit a significantly increased colocalization [70].
In addition, these regions colocalize with an aberrantly
concentrated focus of heterochromatin proteins 1 (HP1)
in G2 phase and with other proteins from promyelocytic
leukemia nuclear bodies [71]. Moreover, these ICF B-cell
lines display abnormal looping of pericentromeric
sequences at metaphase, formation of chromosome
bridges at anaphase, chromosome 1 and 16 fragmenta-
tion at the telophase-interphase transition, increased
apoptosis, and micronuclei with overrepresentation of
chromosome 1 and 16 material [70]. Another source of
anaphase bridging in ICF B-cell lines is a significantly
increased frequency of random telomeric associations
between chromosomes [28,70]. These have not been
described in stimulated ICF lymphocytes. Extensive kary-
otype analysis of ICF B-cell lines suggests that deconden-
sation of 1qh and 16qh often leads to unresolved
Holliday junctions, chromosome breakage, arm missegre-Orphanet Journal of Rare Diseases 2006, 1:2 http://www.OJRD.com/content/1/1/2
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gation, and the formation of more stable translocations
[28]. The findings that ICF B-cell lines and lymphocytes in
vivo are prone to micronucleus formation and apoptosis
[9,70-72] are consistent with the apparently normal cell
cycle checkpoints in ICF B-cell lines [55]. These findings
suggest that in stimulated lymphocytes and B-cell lines
from ICF patients there is continuous generation of 1qh
and 16qh chromosome rearrangements followed by
removal of most of the cells with these chromosomal
abnormalities, which gives rise to a great variety of rear-
rangements at 1qh and 16qh and a lack of clonal abnor-
malities.
4. Why is the exact nature of the immunodeficiency in ICF 
so variable and why are other symptoms of ICF highly 
variable? What is the location and nature of the mutations 
in ICF patients who do not have DNMT3B coding-region 
mutations?
The diverse collection of mutations in the exons of
DNMT3B and the as-yet unmapped other mutations that
cause ICF may explain the variety of symptoms. In addi-
tion, it has been proposed that the polymorphic nature of
the length of the 1qh and 16qh region may contribute to
the variety of phenotypes [71]. However, in non-ICF
patients, no phenotype has been associated with the nat-
ural length-polymorphism of these constitutive hetero-
chromatic regions.
5. Is there a relationship between the hypomethylation of 
the facioscapulohumeral muscular dystrophy (FSHD)-
linked D4Z4 repeat in ICF patients and the much more 
limited hypomethylation of this repeat in short D4Z4 
arrays that cause FSHD?
Curiously, one of the types of DNA repeats found to be
strongly hypomethylated in most ICF B-cell lines com-
pared to controls is the 4q35 and 10q26 D4Z4 repeat
[66,73]. Facioscapulohumeral muscular dystrophy
(FSHD) syndrome, a dominant disease, is almost always
caused by a contraction of these copy-number-polymor-
phic tandem repeats at 4q35 (from 11-100 copies per
locus in unaffected individuals to 1-10 copies in FSHD
patients) although the mechanism for how the array con-
traction causes the disease is unknown [73]. Evidence has
been provided for a significant reduction in methylation
at D4Z4 arrays that have a contracted size [75]. Muscular
dystrophy is not associated with ICF, and so there may not
be a causal connection between D4Z4 hypomethylation
and FSHD.
6. Is there a relationship between invariant 
hypomethylation of satellite 2 DNA sequences in ICF and 
frequent hypomethylation of these same pericentromeric 
repeats in a wide variety of cancers?
There is frequent hypomethylation of satellite 2 at 1qh
and 16qh as well as satellite α in the centromeres of all the
chromosomes in various cancers [76,77]. It has been pro-
posed that this hypomethylation leads to altered gene
expression in trans, as has been hypothesized for ICF lym-
phoid cells [26,76,77]. While the consequences of satellite
2 hypomethylation in ICF and cancer require much more
study, it is already clear that the causes of satellite 2
hypomethylation in cancer and in ICF patients with
DNMT3B-linked disease probably differ. No significant
association between decreased DNMT RNA levels or
increased number of mutations in the DNMT1 gene has
been observed in cancers [78,79]. Furthermore, cancers
typically have hypomethylation in some portions of the
genome and hypermethylation in others [76,78], while
no hypermethylated component has been found in the
ICF genome (unpub. data). Nonetheless, the presently
unknown cause of the hypomethylation of both satellite
2 and satellite α in the ICF cases where DNMT3B muta-
tions have not been found [15] might be related to the
cause of hypomethylation of classical satellite 2 and cen-
tromeric satellite α in cancer.
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